Arterial Stiffness as a Tool to Investigate Adherence in Resistant Hypertension (INSIDE-RH)
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Listed as NCT07207226, this observational or N/A phase trial focuses on Resistant Hypertension and remains ongoing. Sponsored by Institut National de la Santé Et de la Recherche Médicale, France, it has been updated 2 times since 2024, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
2 versions recorded-
Apr 28, 2026 — Present [daily]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting · Phase: NA → None
-
Nov 2025 — Apr 2026 [monthly]
Recruiting NA
First recorded
Nov 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
According to WHO estimates, worldwide, 1.28 billion adults between the age of 30-79 years have hypertension. Furthermore, only 1 in 5 people with hypertension have it under control. In approximately 15% of the patients treated for hypertension, optimum blood pressure levels are not achieved even after the addition of 3-4 conventional anti-hypertensive drugs. These patients are diagnosed as resistant hypertensives. Resistant hypertension is associated with an increased risk of cardiovascular death, myocardial infarction, and stroke. Hypertension is a chronic condition where arterial pressures are persistently elevated, leading to an increase in the pulsatile load on the arteries. This can result in structural and functional alterations in the arterial wall leading to an increase in 'arterial stiffness'. Arterial stiffness is dependent on the mechanical load (blood pressure) and the material properties of the vessel wall. There is a vicious loop between hypertension and arterial stiffness, where hypertension may lead to alteration in the vascular structure and cause degradation of the elastic components of the vessel wall, and an increase in arterial stiffness can lead to higher blood pressure. An increase in arterial stiffness is associated with higher cardiovascular disease (CVD) risk, and patients with resistant hypertension are at a significantly higher risk of developing CVD. Measurement of carotid-femoral pulse wave velocity (PWV) is considered the gold standard for assessing arterial stiffness and has been recommended as a method to evaluate arterial stiffness as a part of routine care in patients with hypertension. The European Society of Hypertension (ESH) and the working group of the European Society of Cardiology (ESC) recommend its use for the evaluation of cardiovascular risk.
Contact Information
- Institut National de la Santé Et de la Recherche Médicale, France
- Medtronic
For direct contact, visit the study record on ClinicalTrials.gov .